Safety of intra-arterial autologous bone marrow mononuclear cell transplantation for acute ischemic stroke

Stroke is the third cause of death and the leading cause of disability in adult subjects. Although stroke mortality has been declining in some countries, stroke morbidity has been increasing due to the aging of population and patients improved survival. Treatment with recombinant tissue plasminogen...

Full description

Saved in:
Bibliographic Details
Published inArquivos brasileiros de cardiologia Vol. 86; no. 1; pp. 52 - 55
Main Authors Mendonça, Maria Lúcia Furtado de, Freitas, Gabriel R de, Silva, Suzana Alves da, Manfrim, Aquiles, Falcão, Carlos Henrique Eiras, Gonzáles, Constantino, André, Charles, Dohmann, Hans Fernando Rocha, Borojevic, Radovan, Otero, Rosália Mendez
Format Journal Article
LanguagePortuguese
Published Brazil 01.01.2006
Subjects
Acute Disease
Bone Marrow Transplantation - methods
Female
Fibrinolytic Agents - therapeutic use
Flow Cytometry
Humans
Injections, Intra-Arterial
Magnetic Resonance Imaging
Middle Aged
Stroke - drug therapy
Stroke - surgery
Tissue Plasminogen Activator - therapeutic use
Tomography, Emission-Computed, Single-Photon
Transplantation, Autologous
Treatment Outcome
Online AccessGet full text

Cover

More Information
Summary:Stroke is the third cause of death and the leading cause of disability in adult subjects. Although stroke mortality has been declining in some countries, stroke morbidity has been increasing due to the aging of population and patients improved survival. Treatment with recombinant tissue plasminogen activator (rtPA) is successful provided it is administered within 3 hours of symptoms onset, but its use is limited to about 5% of the patients with acute ischemic stroke. Furthermore, no neuroprotective agent has yet been proven effective in human clinical trials. The development of other therapeutic strategies is, therefore, warranted. The use of stem cells in animal models has led to functional improvement following stroke. Recent publications have shown that bone marrow mononuclear cells (BM-MNC) therapy through intracoronary injection is a safe procedure in patients with acute or chronic ischemic heart disease. Based on these preliminary data, there has been growing interest in the study of BM-MNC transplantation for acute ischemic stroke. We report the first case of intra-arterial autologous BM-MNC transplantation for acute ischemic stroke.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Report-3
ObjectType-Case Study-4
ISSN:0066-782X